摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-bis(isopentoxy)-2-methylbenzene | 956004-67-4

中文名称
——
中文别名
——
英文名称
1,4-bis(isopentoxy)-2-methylbenzene
英文别名
1,4-bis(3-methylbutoxy)-2-methylbenzene;1,4-bis[3-methylbutoxy]-2-methylbenzene;2-methyl-1,4-bis(3-methylbutoxy)benzene
1,4-bis(isopentoxy)-2-methylbenzene化学式
CAS
956004-67-4
化学式
C17H28O2
mdl
——
分子量
264.408
InChiKey
MRQWPGBPEPYBJZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    349.8±22.0 °C(predicted)
  • 密度:
    0.922±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    19
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Noble ruthenium-type sensitizer and method of preparing the same
    摘要:
    本发明涉及一种钌型染料及其制备方法,更具体地说,涉及一种钌型染料,用于制造染料敏化太阳能电池,显著提高摩尔消光系数,以仅使用少量染料和氧化物半导体粒子来提高太阳能电池的效率,使薄膜太阳能电池元件易于制造,并大幅降低太阳能电池的制造成本,以及其制备方法。
    公开号:
    US08288542B2
  • 作为产物:
    描述:
    甲基氢醌1-溴代异戊烷potassium carbonate 作用下, 以 丙酮 为溶剂, 以59%的产率得到1,4-bis(isopentoxy)-2-methylbenzene
    参考文献:
    名称:
    含有对亚苯基亚乙烯基单元的有机敏化剂的分子工程,用于染料敏化太阳能电池。
    摘要:
    合成了三种有机敏化剂,它们包含双-二甲基芴基氨基供体和对亚苯基亚乙烯基单元桥接的氰基丙烯酸受体。功率转换效率对桥联亚苯基亚乙烯基的长度非常敏感。使用三种敏化剂制备了纳米晶TiO2染料敏化太阳能电池。JK-59的最大功率转换效率达到7.02%。
    DOI:
    10.1021/jo8005182
点击查看最新优质反应信息

文献信息

  • NOBLE RUTHENIUM-TYPE SENSITIZER AND METHOD OF PREPARING THE SAME
    申请人:PARK Chan-seok
    公开号:US20100071763A1
    公开(公告)日:2010-03-25
    The present invention relates to a ruthenium-type dye and a making method thereof, and more particularly, to a ruthenium-type dye which is used to manufacture a dye-sensitized solar cell, drastically improves a molar extinction coefficient to enhance efficiency of a solar cell with only a small amount of a dye and oxide semiconductor particles, allows a thin film solar cell element to be manufactured without difficulty and sharply reduces manufacturing costs of a solar cell, and a making method thereof.
    本发明涉及一种染料及其制备方法,更具体地,涉及一种染料,用于制造染料敏化太阳能电池,显著提高摩尔消光系数,以增强仅使用少量染料和氧化物半导体粒子的太阳能电池的效率,使得可以轻松制造薄膜太阳能电池元件并大幅降低太阳能电池的制造成本,以及其制备方法。
  • MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES
    申请人:MUTO Susumu
    公开号:US20080234233A1
    公开(公告)日:2008-09-25
    A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.
    这是一种用于预防和/或治疗神经退行性疾病,如阿尔茨海默病等的药物,其包括以下通式(I)所表示的化合物中所选的一种作为活性成分,以及其药学上可接受的盐、合物和溶剂化合物:其中,A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基,或单环或融合的多环杂环芳基,可以取代,但是当所述杂环芳基为圆圈1}在公式(I)中直接结合—CONH—基团的环为苯环,圆圈2}未取代的噻唑-2-基团,或圆圈3}未取代的苯并噻唑-2-基团时,排除在外,环Z代表一个芳烃,除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外,还可以有一个或多个取代基,其中A具有上述定义的相同含义,E具有上述定义的相同含义,或者代表一个杂芳烃,除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外,还可以有一个或多个取代基。
  • ANTIALLERGIC AGENTS
    申请人:Muto Susumu
    公开号:US20080090779A1
    公开(公告)日:2008-04-17
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、合物和溶剂化物作为活性成分,其中X表示连接基,其主链中原子数为2至5(该连接基可以被取代),A表示氢原子或乙酰基,E表示芳基或取代的杂芳基,环Z表示苯环,除了由公式-O-A表示的基团,该苯环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同,或者是一个杂环,除了由公式-O-A表示的基团,该杂环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同。
  • Antiallergic agents
    申请人:Muto Susumu
    公开号:US20070185059A1
    公开(公告)日:2007-08-09
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其活性成分包括以下通式(I)表示的化合物或其药学上可接受的盐、合物和溶剂化物中的一种,其中X代表连接基,其主链中的原子数为2到(该连接基可以被取代),A代表氢原子或乙酰基,E代表芳基或取代的杂环芳基,环Z代表芳烃,除了由公式-O-A表示的基团外,还可以有一个或多个取代基,其中A具有上述定义的相同含义,并且由公式-X-E表示的基团,其中X和E的每个都具有上述定义的相同含义,或者可以有一个或多个取代基的杂芳烃,其中A具有上述定义的相同含义,并且由公式-X-E表示的基团,其中X和E的每个都具有上述定义的相同含义。
  • Inhibitors against activation of NF-kappaB
    申请人:MUTO Susumu
    公开号:US20080311074A1
    公开(公告)日:2008-12-18
    A method of inhibiting NF-κB activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
    一种抑制哺乳动物(包括人类)中NF-κB激活的方法,包括以下步骤:给予所选物质的有效剂量,所选物质选自以下组合:一种由下列通式(I)表示的化合物及其药理学上可接受的盐、合物和溶剂化物。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯